Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 363,359,936
  • Shares Outstanding, K 2,684,000
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.79
  • Price/Sales 5.02
  • Price/Cash Flow 16.24
  • Price/Book 5.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
129.72 +4.36%
on 09/05/17
135.77 -0.29%
on 09/18/17
+2.75 (+2.07%)
since 08/18/17
3-Month
129.57 +4.48%
on 07/27/17
137.08 -1.24%
on 07/20/17
+1.03 (+0.77%)
since 06/16/17
52-Week
109.32 +23.84%
on 12/07/16
137.08 -1.24%
on 07/20/17
+17.13 (+14.49%)
since 09/16/16

Most Recent Stories

More News
Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced the appointment...

JNJ : 135.38 (+0.69%)
EDGE : 9.43 (-0.53%)
Exergen Supports Nursing Innovation and Education

For the second consecutive year, Exergen is proud to support Northeastern University Bouve School of Nursing as a Mission Sponsor of the Nurse Innovation and Entrepreneurship program. The School's mission...

JNJ : 135.38 (+0.69%)
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates

: Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.

JNJ : 135.38 (+0.69%)
NVS : 85.11 (-0.55%)
CPRX : 2.43 (+0.83%)
PFE : 35.55 (+0.54%)
J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU

J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.

JNJ : 135.38 (+0.69%)
NVS : 85.11 (-0.55%)
ABBV : 85.32 (-2.35%)
ALXN : 143.64 (-2.08%)
Q2 2017 S&P 500 Buybacks Fall 9.8% from Q1, to $120.1 Billion

S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500® stock buybacks, or share repurchases, totaled $120.1 billion for Q2 2017. This is a 9.8% decrease from the...

GOOGL : 929.75 (-0.59%)
AAPL : 158.67 (-0.76%)
CSCO : 32.52 (+0.25%)
C : 70.60 (+2.26%)
BAC : 24.70 (+1.31%)
JPM : 92.92 (+1.42%)
JNJ : 135.38 (+0.69%)
GS : 227.53 (+1.03%)
DIS : 98.10 (-0.43%)
MSFT : 75.16 (-0.20%)
CMCSA : 37.11 (+0.49%)
IBM : 144.55 (-0.19%)
WFC : 52.71 (+2.03%)
INTC : 37.00 (unch)
V : 104.83 (-0.45%)
SPGI : 154.43 (+0.28%)
CHTR : 368.17 (-0.35%)
HD : 157.81 (-0.37%)
AIG : 59.39 (-0.39%)
BA : 253.08 (+1.64%)
WMT : 80.00 (-0.47%)
Neos Therapeutics ADHD Drug Adzenys Receives Approval in US

Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.

JNJ : 135.38 (+0.69%)
SHPG : 155.66 (-1.77%)
PFE : 35.55 (+0.54%)
NEOS : 8.70 (-5.43%)
S&P 500 Makes History, Steers Past 2500: Top 5 Gainers

The S&P 500, America's dominant stock market index, is in a 'breakout mode' right now as it powered past 2,500 for the first time

SIG : 67.50 (-3.23%)
GNW : 3.99 (-0.25%)
NVDA : 187.55 (+4.13%)
AAPL : 158.67 (-0.76%)
JNJ : 135.38 (+0.69%)
CAT : 123.83 (+2.03%)
XOM : 80.09 (+0.02%)
ANF : 14.08 (-1.12%)
BA : 253.08 (+1.64%)
Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study

Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.

JNJ : 135.38 (+0.69%)
REGN : 434.64 (+0.27%)
PFE : 35.55 (+0.54%)
ALXN : 143.64 (-2.08%)
Amgen/Allergan's Avastin Biosimilar Secures FDA Approval

The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.

JNJ : 135.38 (+0.69%)
AGN : 221.54 (+0.57%)
RHHBY : 31.5725 (-0.47%)
AMGN : 186.47 (-0.53%)
TCS in Fortune 50 List of Companies that Changed the World

Tata Consultancy Services (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been recognized in Fortune's annual list of the Top 50 companies that...

JNJ : 135.38 (+0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 136.75
1st Resistance Point 136.06
Last Price 135.38
1st Support Level 134.40
2nd Support Level 133.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.